ImmuneOnco announces the appointment of Dr. Kathy Yu as Vice President of the Company

On March 30, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced the appointment of Dr. Kathy Yu as Vice President of the Company, with overall responsibility for the Company's BD affairs. Dr.Yu Xiaoxu g......

2021-04-22

ImmuneOnco received ‘Hi-Tech Enterprise Certificate’

On March 05, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter refer to as ImmuneOnco) announced receiving ‘Hi-Tech Enterprise Certificate’. This certificate is jointly issued by Shanghai Municipal Science and Technology Commission, Sh......

2021-04-22

New indications of IMM01 project of ImmuneOnco obtained NMPA clinical trial research license

On January 20, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first Fc fusion protein drug targeting human CD47 (Project No.: IMM01) in China, expanding new indications (AML and MDS) and obtaining NMPA clinical trial research li......

2021-01-20

IMM0306 project of ImmuneOnco has been approved by FDA

On January 9, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the company's self-developed bispecific antibody drug (Project No.: IMM0306) targeting both CD47 and CD20 has obtained the US FDA clinical trial research license. It was o......

2021-01-09

The bispecific antibody drugs targeting PD-L1 and VEGF simultaneously obtained NMPA clinical trial research license

On December 28, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the company's bispecific antibody drug (Project No.: IMM2510) targeting PD-L1 and VEGF has recently obtained the NMPA clinical trial research license (acceptance No.:CXS......

2020-12-28